XBiotech (XBIT) 10-K/A 15 Mar 19 2018 FY Annual report (amended) Financial data

Document And Entity Information

Document And Entity Information - USD ($)	12 Months Ended
	Dec. 31, 2018	Mar. 13, 2019
Document Information [Line Items]
Entity Registrant Name	XBiotech Inc.
Entity Central Index Key	0001626878
Trading Symbol	xbit
Current Fiscal Year End Date	--12-31
Entity Filer Category	Accelerated Filer
Entity Current Reporting Status	Yes
Entity Voluntary Filers	No
Entity Well-known Seasoned Issuer	No
Entity Emerging Growth Company	true
Entity Ex Transition Period	false
Entity Small Business	false
Entity Common Stock, Shares Outstanding (in shares)		36,047,606
Entity Public Float	$ 130,631,560
Entity Shell Company	false
Document Type	10-K/A
Document Period End Date	Dec. 31, 2018
Document Fiscal Year Focus	2018
Document Fiscal Period Focus	FY
Amendment Flag	true
Amendment Description	This Amendment No. 1 on Form 10-K/A is an amendment to the Annual Report on Form 10-K for the year ended December 31, 2018 (the "Report") filed with the Securities and Exchange Commission on March 14, 2019. This Form 10-K/A is being filed for the purpose of correcting the errors regarding ITEM 8. FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA and the previously filed Certifications (filed as Exhibits 31.1 and 31.2). Except as expressly noted herein, this Form 10-K/A does not alter any other part of the content of the Report and does not affect the information originally set forth in the Report, the remaining portions of which have not been amended.

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2018	Dec. 31, 2017
Current assets:
Cash and cash equivalents	$ 15,823	$ 31,768
Prepaid expenses and other current assets	1,193	1,564
Total current assets	17,016	33,332
Property and equipment, net	27,329	29,640
Total assets	44,345	62,972
Current liabilities:
Accounts payable	1,653	1,730
Accrued expenses	1,291	1,062
Total current liabilities	2,944	2,792
Long-term liabilities:
Deferred rent	3	18
Total liabilities	2,947	2,810
Shareholders’ equity:
Preferred Stock, no par value, unlimited shares authorized, no shares outstanding	0	0
Common stock, no par value, unlimited shares authorized, 35,899,772 and 35,439,272 shares outstanding at December 31, 2018 and December 31, 2017, respectively	279,353	277,492
Accumulated other comprehensive loss	(255)	(768)
Accumulated deficit	(237,700)	(216,562)
Total shareholders’ equity	41,398	60,162
Total liabilities and shareholders’ equity	$ 44,345	$ 62,972

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parentheticals) - $ / shares $ / shares in Thousands	Dec. 31, 2018	Dec. 31, 2017
Preferred stock, par value (in dollars per share)	$ 0	$ 0
Preferred stock, shares outstanding (in shares)	0	0
Common stock, par value (in dollars per share)	$ 0	$ 0
Common stock, shares outstanding (in shares)	35,899,772	35,439,272

Consolidated Statements of Oper

Consolidated Statements of Operations - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Operating expenses:
Research and development	$ 15,725	$ 26,424	$ 42,486
General and administrative	5,269	7,635	10,277
Total operating expenses	20,994	34,059	52,763
Loss from operations	(20,994)	(34,059)	(52,763)
Other income (loss):
Interest income	400	354	49
Other income	4
Foreign exchange gain (loss)	(548)	555	(47)
Total other income (loss)	(144)	909	2
Net loss	$ (21,138)	$ (33,150)	$ (52,761)
Net loss per share—basic and diluted (in dollars per share)	$ (0.59)	$ (0.95)	$ (1.63)
Shares used to compute basic and diluted net loss per share (in shares)	35,804,304	34,875,814	32,403,391

Consolidated Statements of Comp

Consolidated Statements of Comprehensive Loss - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Net loss	$ (21,138)	$ (33,150)	$ (52,761)
Foreign currency translation adjustment	513	(825)	258
Comprehensive loss	$ (20,625)	$ (33,975)	$ (52,503)

Consolidated Statements of Shar

Consolidated Statements of Shareholders' Equity - USD ($) shares in Thousands, $ in Thousands	Common Stock [Member]	AOCI Attributable to Parent [Member]	Retained Earnings [Member]	Total
Balance (in shares) at Dec. 31, 2015	32,279
Balance at Dec. 31, 2015	$ 233,902	$ (201)	$ (130,651)	$ 103,050
Net loss			(52,761)	(52,761)
Foreign currency translation adjustment		258		258
Issuance of common stock, net of issuance cost (in shares)	145
Issuance of common stock, net of issuance cost	$ 1,808			1,808
Issuance of common stock under stock option plan (in shares)	204
Issuance of common stock under stock option plan	$ 1,136			1,136
Share-based compensation expense	$ 5,573			5,573
Balance (in shares) at Dec. 31, 2016	32,628
Balance at Dec. 31, 2016	$ 242,419	57	(183,412)	59,064
Net loss			(33,150)	(33,150)
Foreign currency translation adjustment		(825)		(825)
Issuance of common stock, net of issuance cost (in shares)	2,521
Issuance of common stock, net of issuance cost	$ 32,620			32,620
Issuance of common stock under stock option plan (in shares)	290
Issuance of common stock under stock option plan	$ 818			818
Share-based compensation expense	$ 1,635			1,635
Balance (in shares) at Dec. 31, 2017	35,439
Balance at Dec. 31, 2017	$ 277,492	(768)	(216,562)	60,162
Net loss			(21,138)	(21,138)
Foreign currency translation adjustment		513		513
Issuance of common stock, net of issuance cost (in shares)	300
Issuance of common stock, net of issuance cost
Issuance of common stock under stock option plan (in shares)	161
Issuance of common stock under stock option plan	$ 401			401
Share-based compensation expense	$ 1,660			1,660
Subscription receivable (in shares)
Subscription receivable	$ (200)			(200)
Balance (in shares) at Dec. 31, 2018	35,900
Balance at Dec. 31, 2018	$ 279,353	$ (255)	$ (237,700)	$ 41,398

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Operating activities
Net loss	$ (21,138)	$ (33,150)	$ (52,761)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation	2,433	1,484	698
Share-based compensation expense	1,660	1,750	5,573
Gain on disposal of property and equipment
Other non-cash adjustments		401
Changes in operating assets and liabilities:
Prepaid expenses and other current	372	1,041	(617)
Accounts payable	(78)	(2,700)	(981)
Accrued expenses	229	(2,470)	2,066
Deferred rent	(15)	(5)	7
Net cash used in operating activities	(16,537)	(33,649)	(46,015)
Investing activities
Purchase of property and equipment	(122)	(1,405)	(4,746)
Expenditures on building construction			(9,168)
Net cash used in investing activities	(122)	(1,405)	(13,914)
Financing activities
Issuance of common stock and warrants, net		32,620	1,808
Issuance of common stock under stock option plan	201	703	1,136
Net cash provided by financing activities	201	33,323	2,944
Effect of foreign exchange rate on cash and cash equivalents	513	(825)	258
Net change in cash and cash equivalents	(15,945)	(2,556)	(56,727)
Cash and cash equivalents, beginning of period	31,768	34,324	91,051
Cash and cash equivalents, end of period	15,823	31,768	34,324
Supplemental Information:
Accrued purchases of property and equipment			148
Accrued expenditures on building construction			439
Subscription receivable	$ 200

Note 1 - Organization

Note 1 - Organization	12 Months Ended
	Dec. 31, 2018
Notes to Financial Statements
Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]	1. XBiotech Inc. (XBiotech or the Company) was incorporated in Canada on March 22, 2005. November 2007. August 2010. March 2013. January 2014. Since its inception, XBiotech has focused on advancing technology to rapidly identify and clone antibodies from individuals that have resistance to disease. At the heart of the Company is a proprietary technical knowhow to translate natural human immunity into therapeutic product candidates. In 2005, With the manufacturing capability to produce its True Human ™ 2010, first 2 The Company continues to be subject to a number of risks common to companies in similar stages of development. Principal among these risks are the uncertainties of technological innovations, dependence on key individuals, development of the same or similar technological innovations by the Company’s competitors and protection of proprietary technology. The Company’s ability to fund its planned clinical operations, including completion of its planned trials, is expected to depend on the amount and timing of cash receipts from future collaboration or product sales and/or financing transactions. The Company believes that its cash and cash equivalents of $15.8 December 31, 2018, one

Note 2 - Significant Accounting

Note 2 - Significant Accounting Policies	12 Months Ended
	Dec. 31, 2018
Notes to Financial Statements
Significant Accounting Policies [Text Block]	2. Basis of Presentation These consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States (US GAAP). Basis of Consolidation The consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries. All significant intercompany transactions have been eliminated upon consolidation. Use of Estimates The preparation of financial statements in accordance with accounting principles generally accepted in the U.S. requires management to make estimates and assumptions that affect the reported values of amounts in the financial statements and accompanying notes. Actual results could differ from those estimates. Prior to its initial public offering on April 15, 2015, third Research and Development Costs All research and development costs are charged to expense as incurred. Research and development costs include salaries and personnel-related costs, consulting fees, fees paid for contract clinical trial research services, the costs of laboratory consumables, equipment and facilities, license fees and other external costs. Costs incurred to acquire licenses for intellectual property to be used in research and development activities with no Nonrefundable advance payments for goods or services to be received in the future for use in research and development activities are deferred and capitalized. The capitalized amounts are expensed as the related goods are delivered or the services are performed. Income Taxes The Company makes estimates and judgments in determining the need for a provision for income taxes, including the estimation of its taxable income or loss for the full fiscal year. The Company has accumulated significant deferred tax assets that reflect the tax effects of net operating losses and tax credit carryovers and temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. Realization of certain deferred tax assets is dependent upon future earnings. The Company is uncertain about the timing and amount of any future earnings. Accordingly, the Company offsets these deferred tax assets with a valuation allowance. The Company may may The GAAP guidance requires recognition of the impact of a tax position in our financial statements only if that position is more likely than not Share-Based Compensation The Company accounts for its share-based compensation awards in accordance with ASC Topic 718, Compensation-Stock Compensation 718” 718, Share-based compensation expense recognized for the years ended December 31, 2018, 2017 2016 Year Ended 2018 2017 2016 Research and development $ 696 $ 413 $ 2,095 General and administrative 964 2,063 3,478 Total share-based compensation expense $ 1,660 $ 2,476 $ 5,573 No December 31, 2018, 2017 2016. The fair value of each option is estimated on the date of grant using the Black-Scholes method with the following assumptions: Year Ended 2018 2017 2016 Weighted-average grant date fair value per share $4.32 $4.85 $7.29 Expected volatility 67% - 80% 65% - 67% 65% - 70% Risk-free interest rate 2.38% - 3.12% 1.83% - 2.41% 1.09% - 2.44% Expected life (in years) 1 – 10 5.38 – 10 5 – 10 Dividend yield – – – Due to the adoption of ASU No. 2016 09, January 1, 2017, Cash and Cash Equivalents The Company considers highly liquid investments with a maturity of 90 Concentrations of Credit Risk Financial instruments that potentially subject the Company to credit risk consist primarily of cash and cash equivalents. The Company holds these investments in highly-rated financial institutions, and limits the amounts of credit exposure to any one may not not no Fair Value Measurements The Company follows ASC Topic 820, Fair Value Measurements and Disclosures three · Level 1—Unadjusted · Level 2—Quoted not · Level 3—Unobservable At December 31, 2018 2017, not December 31, 2018 2017, Property and Equipment Property and equipment, which consists of land, construction in process, furniture and fixtures, computers and office equipment, scientific equipment, leasehold improvements, vehicles and building are stated at cost and depreciated over the estimated useful lives of the assets, with the exception of land and construction in process which are not · 7 · 5 · Shorter of asset’s useful life or remaining lease term · 5 · 5 · 39 Costs of major additions and betterments are capitalized; maintenance and repairs, which do not Impairment of Long-Lived Assets The Company periodically evaluates its long-lived assets for potential impairment in accordance with ASC Topic 360, Property, Plant and Equipment may not not December 31, 2018. Foreign Currency Transactions Certain transactions are denominated in a currency other than the Company’s functional currency of the U.S. dollar, and the Company generates assets and liabilities that are fixed in terms of the amount of foreign currency that will be received or paid. At each balance sheet date, the Company adjusts the assets and liabilities to reflect the current exchange rate, resulting in a translation gain or loss. Transaction gains and losses are also realized upon a settlement of a foreign currency transaction in determining net loss for the period in which the transaction is settled. Comprehensive Income (Loss) ASC Topic 220, Comprehensive Income Segment and Geographic Information Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision maker, or decision making group, in making decisions on how to allocate resources and assess performance. The Company’s chief operating decision maker is the Chief Executive Officer. The Company and the chief operating decision maker view the Company’s operations and manage its business as one Net Loss per Share Net loss per share (“EPS”) is computed by dividing net loss by the weighted average number of common shares outstanding during each period. Diluted EPS is computed by dividing net loss by the weighted average number of common shares and common share equivalents outstanding (if dilutive) during each period. The number of common share equivalents, which include stock options, is computed using the treasury stock method. Subsequent Events The Company considered events or transactions occurring after the balance sheet date but prior to the date the consolidated financial statements are available to be issued for potential recognition or disclosure in its consolidated financial statements. We have evaluated subsequent events through the date of filing this Form 10 Recent Accounting Pronouncements In February 2016, 842, No. 2016 02, 840, 842 No. 2018 01, 842; No. 2018 10, 842, No. 2018 11, 842, 12 first 2019; January 1, 2019, not not In March 2016, No. 2016 09, January 1, 2017. $491 not not $491 2016 09 no January 1, 2017. one not

Note 3 - Property and Equipment

Note 3 - Property and Equipment and Building Construction in Progress	12 Months Ended
	Dec. 31, 2018
Notes to Financial Statements
Property, Plant and Equipment Disclosure [Text Block]	3. Property and equipment consisted of the following as of December 31, 2018 2017 2018 2017 Computer and office equipment $ 476 $ 461 Furniture and fixtures 183 183 Land 1,418 1,418 Leasehold improvements 802 802 Scientific equipment 12,572 12,194 Vehicle 30 30 Building 21,013 21,013 Construction in process 201 472 Accumulated depreciation (9,366 ) (6,933 ) $ 27,329 $ 29,640 Depreciation expenses related to property and equipment amounted to approximately $2.4 $1.5 $0.7 December 31, 2018, 2017 2016,

Note 4 - Accrued Expenses

Note 4 - Accrued Expenses	12 Months Ended
	Dec. 31, 2018
Notes to Financial Statements
Accounts Payable and Accrued Liabilities Disclosure [Text Block]	4. Accrued expenses consist of the following as of December 31, 2018, 2017 2018 2017 Accrued compensation and related expenses $ 258 $ 234 Accrued professional fees 92 32 Accrued clinical trial expenses 905 766 Other 36 30 $ 1,291 $ 1,062

Note 5 - Common Stock

Note 5 - Common Stock	12 Months Ended
	Dec. 31, 2018
Notes to Financial Statements
Stockholders' Equity Note Disclosure [Text Block]	5. Pursuant to its Articles, the Company has an unlimited number of shares available for issuance with no In February 2017, 87 $12.09 $12.37 $1.0 In March 2017, 2.4 $13.00 $31.6 From January December 2017, 290 $2.50 $14.71 $703 From January December 2018, 161 $2.50 $401 $200

Note 6 - Common Stock Options

Note 6 - Common Stock Options	12 Months Ended
	Dec. 31, 2018
Notes to Financial Statements
Disclosure of Compensation Related Costs, Share-based Payments [Text Block]	6. On November 11, 2005, may may All options will be non-transferable and may first may The term of the options is at the discretion of the Compensation Committee, but may not 10 three The number of common shares reserved for issuance to any one not, 5% A summary of changes in common stock options issued under the Plan is as follows: Options Exercise Price Weighted-Average Options outstanding at December 31, 2015 4,786,577 $0.53 - $21.99 $ 8.56 Granted 1,059,990 7.71 - 19.10 11.72 Exercised (204,159 ) 0.74 - 19.09 5.56 Forfeitures (453,750 ) 0.52 - 16.91 12.79 Options outstanding at December 31, 2016 5,188,658 $0.52 - $21.99 $ 8.49 Granted 1,251,000 4.15 - 12.62 4.85 Exercised (406,667 ) 0.93 - 14.71 2.28 Forfeitures (729,367 ) 0.94 - 21.99 11.90 Options outstanding at December 31, 2017 5,303,624 $2.50 - $21.99 $ 7.69 Granted 1,153,500 2.50 - 5.93 4.32 Exercised (160,500 ) 2.50 2.50 Forfeitures (761,185 ) 2.50 - 19.09 6.12 Options outstanding at December 31, 2018 5,535,439 $2.50 - $21.99 $ 7.30 The weighted average fair value of the options issued to directors, employees and consultants during the fiscal years ended December 31, 2018, 2017 2016, $2.97, $2.97 $7.29, 2.22 3.75 $1.63, 2018, 2017 2016, December 31, 2018 $2.1 $2.9 December 31, 2018, 2017 2016 $1.7 $1.6 $5.7 As of December 31, 2018, $3.0 2.13

Note 7 - Net Loss Per Share

Note 7 - Net Loss Per Share	12 Months Ended
	Dec. 31, 2018
Notes to Financial Statements
Earnings Per Share [Text Block]	7. The following summarizes the computation of basic and diluted net loss per share for the years ended December 31, 2018, 2017 2016 Year Ended December 31, 2018 2017 2016 Net loss $ (21,138 ) $ (33,150 ) $ (52,761 ) Weighted-average number of common shares—basic and diluted 35,804,304 34,875,814 32,403,391 Net loss per share—basic and diluted $ (0.59 ) $ (0.95 ) $ (1.63 ) The following potentially dilutive securities outstanding, prior to the use of the treasury stock method or if-converted method, have been excluded from the computation of diluted weighted-average common shares outstanding, because including them would have had an anti-dilutive effect due to the losses reported. Year Ended December 31, 2018 2017 2016 Stock options 5,535,439 5,303,624 5,188,658 Warrants to purchase common stock - - - Total 5,535,439 5,303,624 5,188,658

Note 8 - Income Taxes

Note 8 - Income Taxes	12 Months Ended
	Dec. 31, 2018
Notes to Financial Statements
Income Tax Disclosure [Text Block]	8. The Company recorded no December 31, 2018, 2017 2016, A reconciliation of the Company’s Canadian federal statutory income tax rate to the Company’s effective income tax rate is as follows for the years ended December 31, 2018, 2017, 2016: 2018 2017 2016 Income tax benefit computed at federal tax rate 26.0 % 26.0 % 26.0 % Change in valuation allowance (20.3 %) (15.3 %) (22.1 %) Impacts of US tax reform - (13.4 %) - Prior year true-ups (2.3 %) - - Stock compensation and other (3.4 %) 2.7 % (3.9 %) Total - % - % - % During the years ended December 31, 2018, 2017 2016, no As of December 31, 2018, 2017, $173.2 $141.7 $30.9 $0.6 $167.6 $132.3 $27.7 $6.7 $0.9 2025 2028 2018 2022 Deferred income taxes reflect the net tax effects of temporary differences between the carrying amount of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. The Company has established a valuation allowance due to uncertainties regarding the realization of deferred tax assets based upon the Company’s lack of earnings history. Significant components of the Company’s deferred tax assets and liabilities as of December 31, 2018, 2017, 2016 2018 2017 2016 Deferred tax assets: Noncapital losses $ 43,474 $ 41,551 $ 35,064 Qualifying research and development credits 3,119 2,833 2,408 Stock based compensation 1,712 1,618 2,737 Share issue costs 128 42 27 Accrued liabilities 229 49 286 Deferred rent 1 4 8 Total deferred tax assets 48,663 46,097 40,530 Deferred tax liabilities: Depreciation 166 282 31 Prepaid assets 55 - - Share issuance costs - 35 16 Total deferred tax liabilities 221 317 47 Net deferred tax asset 48,442 45,780 40,483 Valuation allowance for deferred tax assets (48,442 ) (45,780 ) (40,483 ) Net deferred tax asset including valuation allowance $ - $ - $ - On December 22, 2017, 35% 21%, January 1, 2018. In connection with the initial analysis of the impact of TJCA, the Company remeasured certain deferred tax assets and liabilities based on the rates at which they are expected to reverse in the future, which is generally 21%. 118 2017 2018. 2018, 2017 no December 31, 2017. Due to additional current year losses, the valuation allowance increased by $2.7 December 31, 2018. $5.3 December 31, 2017 34% 21% 2017. The Company applies the accounting guidance in ASC 740 not December 31, 2018 2017, no The Company files federal income tax returns in Canada, U.S, Switzerland, Germany, and Japan. The Company also files income tax returns in the state of Texas in the U.S. The statute of limitations for assessment by local taxing authorities is open for tax years ended after December 2011. no The components of income before income taxes are as follows: (In thousands) Years Ended December 31, 2018 2017 2016 Domestic $ (5,102 ) $ (5,765 ) $ (8,749 ) Canada (15,404 ) (26,034 ) (41,625 ) Other Foreign (632 ) (1,351 ) (2,387 ) Total $ (21,138 ) $ (33,150 ) $ (52,761 ) In November 2015, 2015 17, three December 31, 2016. not

Note 9 - Commitments and Contin

Note 9 - Commitments and Contingencies	12 Months Ended
	Dec. 31, 2018
Notes to Financial Statements
Commitments Disclosure [Text Block]	9. On January 12, 2008, September 15, 2010, second March 20, 2013, 21 February 28, 2015, four two December 31, 2018 $79,000 2019. Rent expense was approximately $782,000, $741,000 $761,000 December 31, 2018, 2017 2016, On October 23, 2018, 459th 1 17 003063 no

Note 10 - Selected Quarterly Fi

Note 10 - Selected Quarterly Financial Data (Unaudited)	12 Months Ended
	Dec. 31, 2018
Notes to Financial Statements
Quarterly Financial Information [Text Block]	10. Selected Quarterly Financial Data (Unaudited) for the year ended December 31, 2018 2017 2018 First Quarter Second Quarter Third Quarter Fourth Quarter Loss from operations (4,150 ) (5,621 ) (5,115 ) (6,108 ) Net Loss (4,069 ) (5,907 ) (5,051 ) (6,111 ) Net loss per share—basic and diluted (0.11 ) (0.16 ) (0.14 ) (0.17 ) 2017 First Quarter Second Quarter Third Quarter Fourth Quarter Loss from operations (10,271 ) (9,688 ) (6,593 ) (7,507 ) Net Loss (10,563 ) (9,133 ) (6,205 ) (7,249 ) Net loss per share—basic and diluted (0.32 ) (0.26 ) (0.18 ) (0.20 )

Significant Accounting Policies

Significant Accounting Policies (Policies)	12 Months Ended
	Dec. 31, 2018
Accounting Policies [Abstract]
Basis of Accounting, Policy [Policy Text Block]	Basis of Presentation These consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States (US GAAP).
Consolidation, Policy [Policy Text Block]	Basis of Consolidation The consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries. All significant intercompany transactions have been eliminated upon consolidation.
Use of Estimates, Policy [Policy Text Block]	Use of Estimates The preparation of financial statements in accordance with accounting principles generally accepted in the U.S. requires management to make estimates and assumptions that affect the reported values of amounts in the financial statements and accompanying notes. Actual results could differ from those estimates. Prior to its initial public offering on April 15, 2015, third
Research and Development Expense, Policy [Policy Text Block]	Research and Development Costs All research and development costs are charged to expense as incurred. Research and development costs include salaries and personnel-related costs, consulting fees, fees paid for contract clinical trial research services, the costs of laboratory consumables, equipment and facilities, license fees and other external costs. Costs incurred to acquire licenses for intellectual property to be used in research and development activities with no Nonrefundable advance payments for goods or services to be received in the future for use in research and development activities are deferred and capitalized. The capitalized amounts are expensed as the related goods are delivered or the services are performed.
Income Tax, Policy [Policy Text Block]	Income Taxes The Company makes estimates and judgments in determining the need for a provision for income taxes, including the estimation of its taxable income or loss for the full fiscal year. The Company has accumulated significant deferred tax assets that reflect the tax effects of net operating losses and tax credit carryovers and temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. Realization of certain deferred tax assets is dependent upon future earnings. The Company is uncertain about the timing and amount of any future earnings. Accordingly, the Company offsets these deferred tax assets with a valuation allowance. The Company may may The GAAP guidance requires recognition of the impact of a tax position in our financial statements only if that position is more likely than not
Share-based Compensation, Option and Incentive Plans Policy [Policy Text Block]	Share-Based Compensation The Company accounts for its share-based compensation awards in accordance with ASC Topic 718, Compensation-Stock Compensation 718” 718, Share-based compensation expense recognized for the years ended December 31, 2018, 2017 2016 Year Ended 2018 2017 2016 Research and development $ 696 $ 413 $ 2,095 General and administrative 964 2,063 3,478 Total share-based compensation expense $ 1,660 $ 2,476 $ 5,573 No December 31, 2018, 2017 2016. The fair value of each option is estimated on the date of grant using the Black-Scholes method with the following assumptions: Year Ended 2018 2017 2016 Weighted-average grant date fair value per share $4.32 $4.85 $7.29 Expected volatility 67% - 80% 65% - 67% 65% - 70% Risk-free interest rate 2.38% - 3.12% 1.83% - 2.41% 1.09% - 2.44% Expected life (in years) 1 – 10 5.38 – 10 5 – 10 Dividend yield – – – Due to the adoption of ASU No. 2016 09, January 1, 2017,
Cash and Cash Equivalents, Policy [Policy Text Block]	Cash and Cash Equivalents The Company considers highly liquid investments with a maturity of 90
Concentration Risk, Credit Risk, Policy [Policy Text Block]	Concentrations of Credit Risk Financial instruments that potentially subject the Company to credit risk consist primarily of cash and cash equivalents. The Company holds these investments in highly-rated financial institutions, and limits the amounts of credit exposure to any one may not not no
Fair Value Measurement, Policy [Policy Text Block]	Fair Value Measurements The Company follows ASC Topic 820, Fair Value Measurements and Disclosures three · Level 1—Unadjusted · Level 2—Quoted not · Level 3—Unobservable At December 31, 2018 2017, not December 31, 2018 2017,
Property, Plant and Equipment, Policy [Policy Text Block]	Property and Equipment Property and equipment, which consists of land, construction in process, furniture and fixtures, computers and office equipment, scientific equipment, leasehold improvements, vehicles and building are stated at cost and depreciated over the estimated useful lives of the assets, with the exception of land and construction in process which are not · 7 · 5 · Shorter of asset’s useful life or remaining lease term · 5 · 5 · 39 Costs of major additions and betterments are capitalized; maintenance and repairs, which do not
Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]	Impairment of Long-Lived Assets The Company periodically evaluates its long-lived assets for potential impairment in accordance with ASC Topic 360, Property, Plant and Equipment may not not December 31, 2018.
Foreign Currency Transactions and Translations Policy [Policy Text Block]	Foreign Currency Transactions Certain transactions are denominated in a currency other than the Company’s functional currency of the U.S. dollar, and the Company generates assets and liabilities that are fixed in terms of the amount of foreign currency that will be received or paid. At each balance sheet date, the Company adjusts the assets and liabilities to reflect the current exchange rate, resulting in a translation gain or loss. Transaction gains and losses are also realized upon a settlement of a foreign currency transaction in determining net loss for the period in which the transaction is settled.
Comprehensive Income, Policy [Policy Text Block]	Comprehensive Income (Loss) ASC Topic 220, Comprehensive Income
Segment Reporting, Policy [Policy Text Block]	Segment and Geographic Information Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision maker, or decision making group, in making decisions on how to allocate resources and assess performance. The Company’s chief operating decision maker is the Chief Executive Officer. The Company and the chief operating decision maker view the Company’s operations and manage its business as one
Earnings Per Share, Policy [Policy Text Block]	Net Loss per Share Net loss per share (“EPS”) is computed by dividing net loss by the weighted average number of common shares outstanding during each period. Diluted EPS is computed by dividing net loss by the weighted average number of common shares and common share equivalents outstanding (if dilutive) during each period. The number of common share equivalents, which include stock options, is computed using the treasury stock method.
Subsequent Events, Policy [Policy Text Block]	Subsequent Events The Company considered events or transactions occurring after the balance sheet date but prior to the date the consolidated financial statements are available to be issued for potential recognition or disclosure in its consolidated financial statements. We have evaluated subsequent events through the date of filing this Form 10
New Accounting Pronouncements, Policy [Policy Text Block]	Recent Accounting Pronouncements In February 2016, 842, No. 2016 02, 840, 842 No. 2018 01, 842; No. 2018 10, 842, No. 2018 11, 842, 12 first 2019; January 1, 2019, not not In March 2016, No. 2016 09, January 1, 2017. $491 not not $491 2016 09 no January 1, 2017. one not

Note 2 - Significant Accounti_2

Note 2 - Significant Accounting Policies (Tables)	12 Months Ended
	Dec. 31, 2018
Notes Tables
Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table Text Block]	Year Ended 2018 2017 2016 Research and development $ 696 $ 413 $ 2,095 General and administrative 964 2,063 3,478 Total share-based compensation expense $ 1,660 $ 2,476 $ 5,573
Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]	Year Ended 2018 2017 2016 Weighted-average grant date fair value per share $4.32 $4.85 $7.29 Expected volatility 67% - 80% 65% - 67% 65% - 70% Risk-free interest rate 2.38% - 3.12% 1.83% - 2.41% 1.09% - 2.44% Expected life (in years) 1 – 10 5.38 – 10 5 – 10 Dividend yield – – –

Note 3 - Property and Equipme_2

Note 3 - Property and Equipment and Building Construction in Progress (Tables)	12 Months Ended
	Dec. 31, 2018
Notes Tables
Property, Plant and Equipment [Table Text Block]	2018 2017 Computer and office equipment $ 476 $ 461 Furniture and fixtures 183 183 Land 1,418 1,418 Leasehold improvements 802 802 Scientific equipment 12,572 12,194 Vehicle 30 30 Building 21,013 21,013 Construction in process 201 472 Accumulated depreciation (9,366 ) (6,933 ) $ 27,329 $ 29,640

Note 4 - Accrued Expenses (Tabl

Note 4 - Accrued Expenses (Tables)	12 Months Ended
	Dec. 31, 2018
Notes Tables
Schedule of Accrued Liabilities [Table Text Block]	2018 2017 Accrued compensation and related expenses $ 258 $ 234 Accrued professional fees 92 32 Accrued clinical trial expenses 905 766 Other 36 30 $ 1,291 $ 1,062

Note 6 - Common Stock Options (

Note 6 - Common Stock Options (Tables)	12 Months Ended
	Dec. 31, 2018
Notes Tables
Share-based Compensation, Stock Options, Activity [Table Text Block]	Options Exercise Price Weighted-Average Options outstanding at December 31, 2015 4,786,577 $0.53 - $21.99 $ 8.56 Granted 1,059,990 7.71 - 19.10 11.72 Exercised (204,159 ) 0.74 - 19.09 5.56 Forfeitures (453,750 ) 0.52 - 16.91 12.79 Options outstanding at December 31, 2016 5,188,658 $0.52 - $21.99 $ 8.49 Granted 1,251,000 4.15 - 12.62 4.85 Exercised (406,667 ) 0.93 - 14.71 2.28 Forfeitures (729,367 ) 0.94 - 21.99 11.90 Options outstanding at December 31, 2017 5,303,624 $2.50 - $21.99 $ 7.69 Granted 1,153,500 2.50 - 5.93 4.32 Exercised (160,500 ) 2.50 2.50 Forfeitures (761,185 ) 2.50 - 19.09 6.12 Options outstanding at December 31, 2018 5,535,439 $2.50 - $21.99 $ 7.30

Note 7 - Net Loss Per Share (Ta

Note 7 - Net Loss Per Share (Tables)	12 Months Ended
	Dec. 31, 2018
Notes Tables
Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]	Year Ended December 31, 2018 2017 2016 Net loss $ (21,138 ) $ (33,150 ) $ (52,761 ) Weighted-average number of common shares—basic and diluted 35,804,304 34,875,814 32,403,391 Net loss per share—basic and diluted $ (0.59 ) $ (0.95 ) $ (1.63 )
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]	Year Ended December 31, 2018 2017 2016 Stock options 5,535,439 5,303,624 5,188,658 Warrants to purchase common stock - - - Total 5,535,439 5,303,624 5,188,658

Note 8 - Income Taxes (Tables)

Note 8 - Income Taxes (Tables)	12 Months Ended
	Dec. 31, 2018
Notes Tables
Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]	2018 2017 2016 Income tax benefit computed at federal tax rate 26.0 % 26.0 % 26.0 % Change in valuation allowance (20.3 %) (15.3 %) (22.1 %) Impacts of US tax reform - (13.4 %) - Prior year true-ups (2.3 %) - - Stock compensation and other (3.4 %) 2.7 % (3.9 %) Total - % - % - %
Schedule of Deferred Tax Assets and Liabilities [Table Text Block]	2018 2017 2016 Deferred tax assets: Noncapital losses $ 43,474 $ 41,551 $ 35,064 Qualifying research and development credits 3,119 2,833 2,408 Stock based compensation 1,712 1,618 2,737 Share issue costs 128 42 27 Accrued liabilities 229 49 286 Deferred rent 1 4 8 Total deferred tax assets 48,663 46,097 40,530 Deferred tax liabilities: Depreciation 166 282 31 Prepaid assets 55 - - Share issuance costs - 35 16 Total deferred tax liabilities 221 317 47 Net deferred tax asset 48,442 45,780 40,483 Valuation allowance for deferred tax assets (48,442 ) (45,780 ) (40,483 ) Net deferred tax asset including valuation allowance $ - $ - $ -
Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block]	(In thousands) Years Ended December 31, 2018 2017 2016 Domestic $ (5,102 ) $ (5,765 ) $ (8,749 ) Canada (15,404 ) (26,034 ) (41,625 ) Other Foreign (632 ) (1,351 ) (2,387 ) Total $ (21,138 ) $ (33,150 ) $ (52,761 )

Note 10 - Selected Quarterly _2

Note 10 - Selected Quarterly Financial Data (Unaudited) (Tables)	12 Months Ended
	Dec. 31, 2018
Notes Tables
Quarterly Financial Information [Table Text Block]	2018 First Quarter Second Quarter Third Quarter Fourth Quarter Loss from operations (4,150 ) (5,621 ) (5,115 ) (6,108 ) Net Loss (4,069 ) (5,907 ) (5,051 ) (6,111 ) Net loss per share—basic and diluted (0.11 ) (0.16 ) (0.14 ) (0.17 ) 2017 First Quarter Second Quarter Third Quarter Fourth Quarter Loss from operations (10,271 ) (9,688 ) (6,593 ) (7,507 ) Net Loss (10,563 ) (9,133 ) (6,205 ) (7,249 ) Net loss per share—basic and diluted (0.32 ) (0.26 ) (0.18 ) (0.20 )

Note 1 - Organization (Details

Note 1 - Organization (Details Textual) - USD ($) $ in Thousands	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Cash and Cash Equivalents, at Carrying Value, Ending Balance	$ 15,823	$ 31,768	$ 34,324	$ 91,051

Note 2 - Significant Accounti_3

Note 2 - Significant Accounting Policies (Details Textual) $ in Thousands	12 Months Ended
	Dec. 31, 2018USD ($)	Dec. 31, 2017USD ($)	Dec. 31, 2016USD ($)	Jan. 01, 2017USD ($)
Employee Service Share-based Compensation, Tax Benefit from Compensation Expense	$ 0	$ 0	$ 0
Impairment of Long-Lived Assets Held-for-use	$ 0
Number of Operating Segments	1
Deferred Tax Assets, Gross, Total	$ 48,663	46,097	40,530
Deferred Tax Assets, Valuation Allowance, Total	$ 48,442	45,780	$ 40,483
Accounting Standards Update 2016-09 [Member]
Deferred Tax Assets, Gross, Total				$ 491
Deferred Tax Assets, Valuation Allowance, Total				$ 491
Furniture and Fixtures [Member]
Property, Plant and Equipment, Useful Life	7 years
Office Equipment [Member]
Property, Plant and Equipment, Useful Life	5 years
Equipment [Member]
Property, Plant and Equipment, Useful Life	5 years
Vehicles [Member]
Property, Plant and Equipment, Useful Life	5 years
Building [Member]
Property, Plant and Equipment, Useful Life	39 years
Fair Value, Measurements, Recurring [Member]
Assets, Fair Value Disclosure	$ 0	0
Financial and Nonfinancial Liabilities, Fair Value Disclosure	$ 0	$ 0

Note 2 - Significant Accounti_4

Note 2 - Significant Accounting Policies - Share-based Compensation Expense (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Share-based compensation expense	$ 1,660	$ 2,476	$ 5,573
Research and Development Expense [Member]
Share-based compensation expense	696	413	2,095
General and Administrative Expense [Member]
Share-based compensation expense	$ 964	$ 2,063	$ 3,478

Note 2 - Significant Accounti_5

Note 2 - Significant Accounting Policies - Stock Option Valuation Assumptions (Details) - $ / shares	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Weighted-average grant date fair value per share (in dollars per share)	$ 4.32	$ 4.85	$ 7.29
Expected volatility
Dividend yield
Minimum [Member]
Expected volatility	67.00%	65.00%	65.00%
Risk-free interest rate	2.38%	1.83%	1.09%
Expected life (Year)	1 year	5 years 138 days	5 years
Maximum [Member]
Expected volatility	80.00%	67.00%	70.00%
Risk-free interest rate	3.12%	2.41%	2.44%
Expected life (Year)	10 years	10 years	10 years

Note 3 - Property and Equipme_3

Note 3 - Property and Equipment and Building Construction in Progress (Details Textual) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Depreciation, Total	$ 2,433	$ 1,484	$ 698

Note 3 - Property and Equipme_4

Note 3 - Property and Equipment and Building Construction in Progress - Property and Equipment, Net (Details) - USD ($) $ in Thousands	Dec. 31, 2018	Dec. 31, 2017
Accumulated depreciation	$ (9,366)	$ (6,933)
	27,329	29,640
Office Equipment [Member]
Property, plant, and equipment, gross	476	461
Furniture and Fixtures [Member]
Property, plant, and equipment, gross	183	183
Land [Member]
Property, plant, and equipment, gross	1,418	1,418
Leasehold Improvements [Member]
Property, plant, and equipment, gross	802	802
Scientific Equipment [Member]
Property, plant, and equipment, gross	12,572	12,194
Vehicles [Member]
Property, plant, and equipment, gross	30	30
Building [Member]
Property, plant, and equipment, gross	21,013	21,013
Construction in Progress [Member]
Property, plant, and equipment, gross	$ 201	$ 472

Note 4 - Accrued Expenses - Acc

Note 4 - Accrued Expenses - Accrued Expenses (Details) - USD ($) $ in Thousands	Dec. 31, 2018	Dec. 31, 2017
Accrued compensation and related expenses	$ 258	$ 234
Accrued professional fees	92	32
Accrued clinical trial expenses	905	766
Other	36	30
	$ 1,291	$ 1,062

Note 5 - Common Stock (Details

Note 5 - Common Stock (Details Textual) - USD ($) $ / shares in Units, $ in Thousands	1 Months Ended		12 Months Ended
	Mar. 31, 2017	Feb. 28, 2017	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Common Stock, No Par Value			$ 0	$ 0
Stock Issued During Period, Shares, New Issues	2,400,000	87,000
Shares Issued, Price Per Share	$ 13
Proceeds from Issuance of Common Stock	$ 31,600	$ 1,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period			160,500	406,667	204,159
Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price			$ 2.50
Proceeds from Stock Options Exercised			$ 401	$ 703
Stockholders' Equity Note, Subscriptions Receivable			$ 200
Minimum [Member]
Shares Issued, Price Per Share		$ 12.09
Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price				$ 2.50	$ 0.74
Maximum [Member]
Shares Issued, Price Per Share		$ 12.37
Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price				$ 14.71	$ 19.09

Note 6 - Common Stock Options_2

Note 6 - Common Stock Options (Details Textual) - USD ($)	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value	$ 4.32	$ 4.85	$ 7.29
Employee Service Share-based Compensation, Nonvested Awards, Compensation Not yet Recognized, Stock Options	$ 3,000,000
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition	2 years 47 days
The Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value	$ 2.97	2.97	7.29
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Intrinsic Value, Amount Per Share	$ 2.22	$ 3.75	$ 1.63
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value	$ 2.10	$ 2,900,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value	$ 1.70	$ 1.60	$ 5.70
The Plan [Member] | Any One Person [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Percentage of Outstanding Stock Maximum	5.00%
The Plan [Member] | Employee Stock Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period	10 years

Note 6 - Common Stock Options -

Note 6 - Common Stock Options - Changes in Common Stock Options Issued (Details) - $ / shares	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Options outstanding (in shares)	5,303,624	5,188,658	4,786,577
Granted (in shares)	1,153,500	1,251,000	1,059,990
Exercised (in shares)	(160,500)	(406,667)	(204,159)
Exercised, exercise price (in dollars per share)	$ 2.50
Forfeitures (in shares)	(761,185)	(729,367)	(453,750)
Options outstanding (in shares)	5,535,439	5,303,624	5,188,658
Minimum [Member]
Options outstanding, exercise price (in dollars per share)	$ 2.50	$ 0.52	$ 0.53
Granted, exercise price (in dollars per share)	2.50	4.15	7.71
Exercised, exercise price (in dollars per share)		2.50	0.74
Forfeitures, exercise price (in dollars per share)	2.50	0.94	0.52
Options outstanding, exercise price (in dollars per share)	2.50	2.50	0.52
Maximum [Member]
Options outstanding, exercise price (in dollars per share)	21.99	21.99	21.99
Granted, exercise price (in dollars per share)	5.93	12.62	19.10
Exercised, exercise price (in dollars per share)		14.71	19.09
Forfeitures, exercise price (in dollars per share)	19.09	21.99	16.91
Options outstanding, exercise price (in dollars per share)	21.99	21.99	21.99
Weighted Average [Member]
Options outstanding, exercise price (in dollars per share)	7.69	8.49	8.56
Granted, exercise price (in dollars per share)	4.32	4.85	11.72
Exercised, exercise price (in dollars per share)	2.50	2.28	5.56
Forfeitures, exercise price (in dollars per share)	6.12	11.90	12.79
Options outstanding, exercise price (in dollars per share)	$ 7.30	$ 7.69	$ 8.49

Note 7 - Net Loss Per Share - C

Note 7 - Net Loss Per Share - Computation of Basic and Diluted Net Loss Per Share (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended								12 Months Ended
	Dec. 31, 2018	Sep. 30, 2018	Jun. 30, 2018	Mar. 31, 2018	Dec. 31, 2017	Sep. 30, 2017	Jun. 30, 2017	Mar. 31, 2017	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Net loss	$ (6,111)	$ (5,051)	$ (5,907)	$ (4,069)	$ (7,249)	$ (6,205)	$ (9,133)	$ (10,563)	$ (21,138)	$ (33,150)	$ (52,761)
Weighted-average number of common shares—basic and diluted (in shares)									35,804,304	34,875,814	32,403,391
Net loss per share—basic and diluted (in dollars per share)	$ (0.17)	$ (0.14)	$ (0.16)	$ (0.11)	$ (0.20)	$ (0.18)	$ (0.26)	$ (0.32)	$ (0.59)	$ (0.95)	$ (1.63)

Note 7 - Net Loss Per Share - P

Note 7 - Net Loss Per Share - Potentially Dilutive Securities Outstanding (Details) - shares	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Antidilutive securities (in shares)	5,535,439	5,303,624	5,188,658
Employee Stock Option [Member]
Antidilutive securities (in shares)	5,535,439	5,303,624	5,188,658
Warrant [Member]
Antidilutive securities (in shares)

Note 8 - Income Taxes (Details

Note 8 - Income Taxes (Details Textual) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Income Tax Expense (Benefit), Total	$ 0	$ 0	$ 0
Income Tax Examination, Penalties and Interest Expense, Total	0	0	$ 0
Operating Loss Carryforwards, Total	173,200	167,600
Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount	2,700	5,300
Unrecognized Tax Benefits, Ending Balance	0	0
Domestic Tax Authority [Member] | Canada Revenue Agency [Member]
Operating Loss Carryforwards, Total	141,700	132,300
Foreign Tax Authority [Member] | Internal Revenue Service (IRS) [Member]
Operating Loss Carryforwards, Total	30,900	27,700
Foreign Tax Authority [Member] | Swiss Federal Tax Administration (FTA) [Member]
Operating Loss Carryforwards, Total	$ 600	900
Foreign Tax Authority [Member] | Federal Ministry of Finance, Germany [Member]
Operating Loss Carryforwards, Total		6,700
Foreign Tax Authority [Member] | National Tax Agency, Japan [Member]
Operating Loss Carryforwards, Total		$ 900

Note 8 - Income Taxes - Reconci

Note 8 - Income Taxes - Reconciliation of Canadian Federal Statutory Income Tax Rate (Details)	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Income tax benefit computed at federal tax rate	26.00%	26.00%	26.00%
Change in valuation allowance	(20.30%)	(15.30%)	(22.10%)
Impacts of US tax reform		(13.40%)
Prior year true-ups	(2.30%)
Stock compensation and other	(3.40%)	2.70%	(3.90%)
Total

Note 8 - Income Taxes - Signifi

Note 8 - Income Taxes - Significant Components of Deferred Tax Assets and Liabilities (Details) - USD ($) $ in Thousands	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Deferred tax assets:
Noncapital losses	$ 43,474	$ 41,551	$ 35,064
Qualifying research and development credits	3,119	2,833	2,408
Stock based compensation	1,712	1,618	2,737
Share issue costs	128	42	27
Accrued liabilities	229	49	286
Deferred rent	1	4	8
Total deferred tax assets	48,663	46,097	40,530
Deferred tax liabilities:
Depreciation	166	282	31
Prepaid assets	55
Share issuance costs		35	16
Total deferred tax liabilities	221	317	47
Net deferred tax asset	48,442	45,780	40,483
Valuation allowance for deferred tax assets	(48,442)	(45,780)	(40,483)
Net deferred tax asset including valuation allowance

Note 8 - Income Taxes - Compone

Note 8 - Income Taxes - Components of Income Before Income Taxes (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Domestic	$ (5,102)	$ (5,765)	$ (8,749)
Total	(21,138)	(33,150)	(52,761)
CANADA
Canada	(15,404)	(26,034)	(41,625)
Other Foreign [Member]
Canada	$ (632)	$ (1,351)	$ (2,387)

Note 9 - Commitments and Cont_2

Note 9 - Commitments and Contingencies (Details Textual) - USD ($)	Feb. 28, 2015	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016	Mar. 20, 2013
Lessee, Operating Lease, Renewal Term	4 years				1 year 270 days
Lessee Leasing Arrangements, Operating Leases, Early Termination Right	2 years
Operating Leases, Rent Expense, Net, Total		$ 79,000	$ 741,000	$ 761,000

Note 10 - Selected Quarterly _3

Note 10 - Selected Quarterly Financial Data (Unaudited) - Quarterly Financial Data (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended								12 Months Ended
	Dec. 31, 2018	Sep. 30, 2018	Jun. 30, 2018	Mar. 31, 2018	Dec. 31, 2017	Sep. 30, 2017	Jun. 30, 2017	Mar. 31, 2017	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Loss from operations	$ (6,108)	$ (5,115)	$ (5,621)	$ (4,150)	$ (7,507)	$ (6,593)	$ (9,688)	$ (10,271)	$ (20,994)	$ (34,059)	$ (52,763)
Net Loss	$ (6,111)	$ (5,051)	$ (5,907)	$ (4,069)	$ (7,249)	$ (6,205)	$ (9,133)	$ (10,563)	$ (21,138)	$ (33,150)	$ (52,761)
Net loss per share—basic and diluted (in dollars per share)	$ (0.17)	$ (0.14)	$ (0.16)	$ (0.11)	$ (0.20)	$ (0.18)	$ (0.26)	$ (0.32)	$ (0.59)	$ (0.95)	$ (1.63)